Clinical trial · no report yet · Phase 3
SABR-SYNC
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
- NCT05717166 ↗
- Recruiting
- David Palma
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 12 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Tumor
- Interventions
- Palliative Radiotherapy; Chemotherapy; Hormone therapy; Immunotherapy; Targeted Systemic Therapy; Observation; Stereotactic Ablative Radiotherapy; Surgery; Radiofrequency Therapy (RFA); Fractionated Radiation
- Arms
- Standard Arm (Arm 1) · Active comparator
- Experimental Arm (Arm 2) · Experimental
- Enrollment
- 180 (estimated)
- Primary outcomes
- Overall Survival
- Sponsor
- David Palma
- Start
- Oct 6, 2023
- Primary completion
- Apr 2029 (estimated)
- Results posted
- No
- Registry record
- NCT05717166 · updated Dec 31, 2025
Publications
linked from the registry- Palma DA, Giuliani ME, Correa RJM, Schneiders FL, Harrow S, Guckenberger M, Zhang T, Bahig H, Senthi S, Chung P, Olson R, Lock M, Raman S, Bauman GS, Lok BH, Laba JM, Glicksman RM, Nguyen TK, Lang P, Helou J, Goodman CD, Mendez LC, van Rossum PSN, Warner A, Gaede S, Allan AL. A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol. BMC Palliat Care. 2024 Sep 7;23(1):223. doi: 10.1186/s12904-024-01548-7. PubMed 39244532